Clinical Trials Logo
  1. Home
  2. Pyrexia
  3. NCT04652258

Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy — Nov IIT- Pyrex  

Pyrexia Clinical Trial

Official title:
A Phase II, Open Label, Single Arm, Single Center Study to Evaluate Pyrexia Management (With or Without Any Other Cytokine Release Symptoms) Using Tocilizumab, an Humanized Monoclonal Antibody Against the Interleukin - 6 Receptor in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy

Clinical Trial Summary

The study examines the development of fever after administration of Actemra (tocilizumab) in patients who have fever and other cytokine release symptoms (headache, nausea, palpitations, low blood pressure) due to cancer therapy (Tafinlar (dabrafenib) / Mekinist (trametinib) +/- immunotherapy) . The goal of the study is to better understand the side effects and to find an effective therapy against them.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04652258
Study type Interventional
Source University of Zurich
Contact
Status Recruiting
Phase Phase 2
Start date December 1, 2020
Completion date October 1, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04397380 - COVID-19 Thales Thermography Triage : Thermal Camera Feasibility Study
Completed NCT01078519 - Combined Anesthesia for Labor and Maternal Temperature Phase 3
Completed NCT00438269 - Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection Phase 2